How Common Is Rebound After Untreated SARS-CoV-2 Infection?

Transient symptomatic or viral rebound was observed in up to one third of subjects with untreated mild to moderate COVID-19.

Rebound of symptoms and reversion to positive testing after viral clearance can occur after treatment with nirmatrelvir-ritonavir (https://emergency.cdc.gov/han/2022/pdf/CDC_HAN_467.pdf) — however, rebound in untreated patients has not been well studied. Investigators analyzed data from 563 placebo recipients in the ACTIV-2/A5401 trial with mild-to-moderate COVID-19 to assess the natural course of symptomatic and viral rebound. Participants recorded symptoms daily for 28 days, with collection of anterior nasal swabs daily for 14 days and on days 21 and 28.

Symptom rebound occurred in 26% of participants a median 11 days after symptom onset, with 5% determined to have rebound based on hospitalization. Risk factors for symptomatic rebound incl…

Reviewing Author

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

How Common Is Rebound After Untreated SARS-CoV-2 Infection?

Topics

Reviewing Author